Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19700573 | 0.89 | HRH3 (0.45) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL19700578 | 0.89 | HRH3 (0.45) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL19700572 | 0.89 | HRH3 (0.45) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL824023 | 0.89 | CARM1 (0.47) | HRH3MAOBSIGMAR1KDM4ERECQL | |
| SCHEMBL26972452 | 0.84 | HRH3 (0.40) | HRH3MAOB | |
| SCHEMBL10025517 | 0.84 | GNAI3 (0.51) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL21667849 | 0.80 | HRH3 (0.45) | HRH3MAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL823898 | 0.80 | HRH3 (0.49) | HRH3MAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL26787071 | 0.80 | HRH3 (0.55) | HRH3MAOBKDM4EHRH2HRH1 | |
| SCHEMBL26787061 | 0.80 | HRH3 (0.55) | HRH3MAOBKDM4EHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | HRH3 1601/4885MAOB 558/4885SIGMAR1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.